These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

550 related items for PubMed ID: 22975763

  • 21. Boceprevir for untreated chronic HCV genotype 1 infection.
    Poordad F, McCone J, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki JP, SPRINT-2 Investigators.
    N Engl J Med; 2011 Mar 31; 364(13):1195-206. PubMed ID: 21449783
    [Abstract] [Full Text] [Related]

  • 22. Addition of boceprevir to PEG-interferon/ribavirin in HIV-HCV-Genotype-1-coinfected, treatment-experienced patients: efficacy, safety, and pharmacokinetics data from the ANRS HC27 study.
    Poizot-Martin I, Bellissant E, Garraffo R, Colson P, Piroth L, Solas C, Renault A, Bourlière M, Halfon P, Ghosn J, Alric L, Naqvi A, Carrieri P, Molina JM, ANRS HC27 BOCEPREVIH Study Group.
    HIV Clin Trials; 2016 Mar 31; 17(2):63-71. PubMed ID: 27077673
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. [FIRST GENERATION PROTEASE INHIBITOR BASED TRIPLE THERAPY FOR HCV GENOTYPE 1--LOOKING BACK WHILE PROCEEDING TO A PROMISING ERA].
    Ben Yakov G, Montano D, Abu Freha N, Etzion O, Dizingof V, Mushkalo A, Shwarts D, Monitin S, Takchick A, Zilberman D, Sikuler E, Fich A.
    Harefuah; 2016 May 31; 155(5):272-5, 324, 323. PubMed ID: 27526553
    [Abstract] [Full Text] [Related]

  • 25. Adherence to assigned dosing regimen and sustained virological response among chronic hepatitis C genotype 1 patients treated with boceprevir plus peginterferon alfa-2b/ribavirin.
    Gordon SC, Yoshida EM, Lawitz EJ, Bacon BR, Sulkowski MS, Davis M, Poordad F, Bronowicki JP, Esteban R, Sniukiene V, Burroughs MH, Deng W, Dutko FJ, Brass CA, Albrecht JK, Rajender Reddy K.
    Aliment Pharmacol Ther; 2013 Jul 31; 38(1):16-27. PubMed ID: 23710734
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. [Side-effects of pegylated interferon plus ribavirin therapy with or without protease inhibitor direct acting antiviral agents during treatment of chronic hepatitis C virus infection].
    Hunyady B, Kovács B, Battyáni Z.
    Orv Hetil; 2011 Dec 11; 152(50):1997-2009. PubMed ID: 22112373
    [Abstract] [Full Text] [Related]

  • 30. Efficacy and safety of boceprevir plus peginterferon-ribavirin in patients with HCV G1 infection and advanced fibrosis/cirrhosis.
    Bruno S, Vierling JM, Esteban R, Nyberg LM, Tanno H, Goodman Z, Poordad F, Bacon B, Gottesdiener K, Pedicone LD, Albrecht JK, Brass CA, Thompson S, Burroughs MH.
    J Hepatol; 2013 Mar 11; 58(3):479-87. PubMed ID: 23183529
    [Abstract] [Full Text] [Related]

  • 31. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial.
    Forns X, Lawitz E, Zeuzem S, Gane E, Bronowicki JP, Andreone P, Horban A, Brown A, Peeters M, Lenz O, Ouwerkerk-Mahadevan S, Scott J, De La Rosa G, Kalmeijer R, Sinha R, Beumont-Mauviel M.
    Gastroenterology; 2014 Jun 11; 146(7):1669-79.e3. PubMed ID: 24602923
    [Abstract] [Full Text] [Related]

  • 32. Boceprevir: a review of its use in the management of chronic hepatitis C genotype 1 infection.
    Garnock-Jones KP.
    Drugs; 2012 Dec 24; 72(18):2431-56. PubMed ID: 23231027
    [Abstract] [Full Text] [Related]

  • 33. Mericitabine and Either Boceprevir or Telaprevir in Combination with Peginterferon Alfa-2a plus Ribavirin for Patients with Chronic Hepatitis C Genotype 1 Infection and Prior Null Response: The Randomized DYNAMO 1 and DYNAMO 2 Studies.
    Wedemeyer H, Forns X, Hézode C, Lee SS, Scalori A, Voulgari A, Le Pogam S, Nájera I, Thommes JA.
    PLoS One; 2016 Dec 24; 11(1):e0145409. PubMed ID: 26752189
    [Abstract] [Full Text] [Related]

  • 34. Hepatitis C genotype 1 virus with low viral load and rapid virologic response to peginterferon/ribavirin obviates a protease inhibitor.
    Pearlman BL, Ehleben C.
    Hepatology; 2014 Jan 24; 59(1):71-7. PubMed ID: 23873583
    [Abstract] [Full Text] [Related]

  • 35. A network meta-analysis to compare simeprevir with boceprevir and telaprevir in combination with peginterferon-α and ribavirin in patients infected with genotype 1 Hepatitis C virus.
    Taieb V, Pacou M, Ho S, Pettré S, Van Sanden S, Pisini M, Ustianowski A, Mehnert A.
    J Med Econ; 2015 Jan 24; 18(10):787-96. PubMed ID: 25934147
    [Abstract] [Full Text] [Related]

  • 36. Resistance-associated amino acid variants associated with boceprevir plus pegylated interferon-α2b and ribavirin in patients with chronic hepatitis C in the SPRINT-1 trial.
    Ogert RA, Howe JA, Vierling JM, Kwo PY, Lawitz EJ, McCone J, Schiff ER, Pound D, Davis MN, Gordon SC, Ravendhran N, Rossaro L, Jacobson IM, Ralston R, Chaudhri E, Qiu P, Pedicone LD, Brass CA, Albrecht JK, Barnard RJ, Hazuda DJ, Howe AY.
    Antivir Ther; 2013 Jan 24; 18(3):387-97. PubMed ID: 23406826
    [Abstract] [Full Text] [Related]

  • 37. Cost-effectiveness analysis of triple therapy with protease inhibitors in treatment-naive hepatitis C patients.
    Blázquez-Pérez A, San Miguel R, Mar J.
    Pharmacoeconomics; 2013 Oct 24; 31(10):919-31. PubMed ID: 24000086
    [Abstract] [Full Text] [Related]

  • 38. A comparison of peginterferon α-2a and α-2b for treatment-naive patients with chronic hepatitis C virus: A meta-analysis of randomized trials.
    Zhao S, Liu E, Chen P, Cheng D, Lu S, Yu Q, Wang Y, Wei K, Yang P.
    Clin Ther; 2010 Aug 24; 32(9):1565-77. PubMed ID: 20974315
    [Abstract] [Full Text] [Related]

  • 39. Predicting early and sustained virological responses in prior nonresponders to pegylated interferon alpha-2b plus ribavirin retreated with peginterferon alpha-2a plus ribavirin and the benefit-risk ratio of retreatment.
    Marcellin P, Craxi A, Brandao-Mello CE, Di Bisceglie AM, Andreone P, Freilich B, Rajender Reddy K, Olveira Martín A, Teuber G, Messinger D, Hooper G, Wat C, Tatsch F, Jensen DM.
    J Clin Gastroenterol; 2013 Oct 24; 47(9):786-93. PubMed ID: 23442834
    [Abstract] [Full Text] [Related]

  • 40. Impact of ribavirin on HCV replicon RNA decline during treatment with interferon-α and the protease inhibitors boceprevir or telaprevir.
    Hofmann WP, Chung TL, Osbahr C, Susser S, Karey U, Mihm U, Welsch C, Lötsch J, Sarrazin C, Zeuzem S, Herrmann E.
    Antivir Ther; 2011 Oct 24; 16(5):695-704. PubMed ID: 21817191
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 28.